ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy-Reference-Cited by-同舟云学术

ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy

Published:2009-07-01 Issue:7 Volume:4 Page:e6124
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Aceves-Luquero Clara I.,Agarwal Anupriya,Callejas-Valera Juan L.,Arias-González Laura,Esparís-Ogando Azucena,del Peso Ovalle Luis,Bellón-Echeverria Itxaso,de la Cruz-Morcillo Miguel A.,Galán Moya Eva M.,Gimeno Inmaculada Moreno,Gómez Juan C.,Deininger Michael W.,Pandiella Atanasio,Prieto Ricardo Sánchez

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia;Journal of Mass Spectrometry and Advances in the Clinical Lab;2023-04

2. Investigating the Activity of Indole-2-on Derivative Src Kinase Inhibitors Against Chronic Myeloid Leukemia Cells;Anti-Cancer Agents in Medicinal Chemistry;2023-01

3. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph ⁺ chronic myeloid leukemia;American Journal of Hematology;2022-07-18

4. Verbascoside potentiates the effect of tyrosine kinase inhibitors on the induction of apoptosis and oxidative stress via the Abl-mediated MAPK signalling pathway in chronic myeloid leukaemia;Experimental and Therapeutic Medicine;2022-06-14

5. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions;Blood Reviews;2021-09